TD Capital Management
VRTX icon

TD Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

TD Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$42.9K Hold
82
– – ﹤0.01% 264
2026
Q2 		$40.7K Hold
82
– – ﹤0.01% 267
2026
Q1 		$36.6K Buy
82
+7
+9% +$3.26K ﹤0.01% 285
2025
Q4 		$34K Hold
75
– – ﹤0.01% 281
2025
Q3 		$29.4K Hold
75
– – ﹤0.01% 277
2025
Q2 		$33.4K Buy
75
+73
+3,650% +$33.6K ﹤0.01% 258
2025
Q1 		$970 Hold
2
– – ﹤0.01% 557
2024
Q4 		$805 Buy
+2
New +$927 ﹤0.01% 548

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

TD Capital Management's VRTX Position: Q3 2026 in Review

TD Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 82 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #264.

TD Capital Management first reported a position in VRTX in Q4 2024 and has held it in 8 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • TD Capital Management held 82 shares of Vertex Pharmaceuticals worth $42.9K as of Q3 2026.
  • TD Capital Management left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of TD Capital Management's portfolio in Q3 2026, its #264 holding.
  • TD Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on TD Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.